Literature DB >> 27910217

Disentangling estimands and the intention-to-treat principle.

Ann-Kristin Leuchs1, Andreas Brandt1, Jörg Zinserling1, Norbert Benda1.   

Abstract

Randomized controlled trials (RCTs) aim at providing reliable estimates of treatment benefit. Missing data and nonadherence to treatment are distinct problems that can substantially impede this task. In practice, the fact that the handling of missing data due to nonadherence affects the question that is addressed is often ignored. Estimands allow precisely predefining the question of interest. Estimands are definitions of that which is being estimated with regard to population, endpoint, and handling of postrandomization events (eg, nonadherence). Depending on the situation, different estimands are of relevance. Therefore, it is important that the intention-to-treat (ITT) principle, which is considered the gold standard for analyzing RCTs, does not restrict an RCT's primary objective to only one of several relevant estimands. Although much ambiguity is involved around what is considered to constitute the ITT principle, many associate ITT with completely following up all patients and including all data of all randomized patients as allocated into the analysis. This would restrict primary objectives to estimating the effect of treatment policy and is certainly not warranted in all situations. To maintain the advantage of having the clear recommendation to follow the ITT principle while allowing for various relevant estimands as primary objective, we argue that the appropriate way forward is to define ITT as including all randomized patients into the analysis set and each patient is to be allocated to his or her randomized treatment. This definition comprises the actual intent of ITT and can be fully implemented also in settings where complete follow-up is impossible.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ICH E9; causality; clinical trials; missing data; nonadherence; selection bias

Mesh:

Year:  2016        PMID: 27910217     DOI: 10.1002/pst.1791

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  7 in total

1.  Longitudinal Assessment of Pharmacy Students' Confidence and Skill in Providing Evidence-based Answers to Clinical Questions.

Authors:  Amanda Margolis; Shweta Shah; Connie Kraus; Denise Walbrandt Pigarelli
Journal:  Am J Pharm Educ       Date:  2020-10       Impact factor: 2.047

Review 2.  Essential statistical principles of clinical trials of pain treatments.

Authors:  Robert H Dworkin; Scott R Evans; Omar Mbowe; Michael P McDermott
Journal:  Pain Rep       Date:  2020-12-18

3.  Estimands-A Basic Element for Clinical Trials.

Authors:  Moritz Pohl; Lukas Baumann; Rouven Behnisch; Marietta Kirchner; Johannes Krisam; Anja Sander
Journal:  Dtsch Arztebl Int       Date:  2021-12-27       Impact factor: 5.594

4.  Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data with Informative Censoring.

Authors:  Guoqing Diao; Guanghan F Liu; Donglin Zeng; Yilong Zhang; Gregory Golm; Joseph F Heyse; Joseph G Ibrahim
Journal:  Stat Biopharm Res       Date:  2020-11-05       Impact factor: 1.586

5.  Treatment estimands in clinical trials of patients hospitalised for COVID-19: ensuring trials ask the right questions.

Authors:  Brennan C Kahan; Tim P Morris; Ian R White; Conor D Tweed; Suzie Cro; Darren Dahly; Tra My Pham; Hanif Esmail; Abdel Babiker; James R Carpenter
Journal:  BMC Med       Date:  2020-09-09       Impact factor: 8.775

6.  Estimands and missing data in clinical trials of chronic pain treatments: advances in design and analysis.

Authors:  Xueya Cai; Jennifer S Gewandter; Hua He; Dennis C Turk; Robert H Dworkin; Michael P McDermott
Journal:  Pain       Date:  2020-10       Impact factor: 7.926

7.  Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: Specification of mixed models for longitudinal data in study protocols.

Authors:  Sebastian Häckl; Armin Koch; Florian Lasch
Journal:  Pharm Stat       Date:  2019-07-03       Impact factor: 1.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.